Table 4.
Acute and medium-term adverse events.
| Patients: n = 288 | Acute | Medium-term |
|---|---|---|
| Skin adverse events | 278 (96.5%) | 152 (53.1%) |
| Grade 1 | 172 (59.7%) | 147 (51.0%) |
| Grade 2 | 102 (35.4%) | 2 (0.6%) |
| Grade 3 | 4 (1.4%) | 2 (0.6%) |
| Esophageal adverse events | 138 (47.9%) | 6 (2.1%) |
| Grade 1 | 120 (41.7%) | 6 (2.1%) |
| Grade 2 | 18 (6.3%) | - |
| Edema | 57 (19.8%) | 69 (24.1%) |
| Grade 1 | 55 (19.1%) | 63 (22.0%) |
| Grade 2 | 1 (0.3%) | 5 (1.7%) |
| Grade unknown | 1 (0.3%) | 1 (0.3%) |
| Parietal fibrosis (total mastectomy, n = 120) | 36 (30.0%) | 51 (42.9%) |
| Grade 1 | 34 (28.3%) | 42 (35.3%) |
| Grade 2 | 2 (1.7%) | 9 (7.6%) |
| Breast fibrosis (partial mastectomy, n = 168) | 57 (33.9%) | 68 (40.7%) |
| Grade 1 | 54 (32.1%) | 59 (35.3%) |
| Grade 2 | 2 (1.2%) | 9 (5.4%) |
| Grade unknown | 1 (0.6%) | - |
| Surgical scar fibrosis (total mastectomy, n = 98) | 20 (20.4% %) | 52 (44.1%) |
| Grade 1 | 18 (18.4%) | 45 (38.1%) |
| Grade 2 | 2 (2.0%) | 7 (5.9%) |
| Surgical bed fibrosis (partial mastectomy, n = 165) | 31 (18.8%) | 66 (39.5%) |
| Grade 1 | 29 (17.6%) | 56 (33.5%) |
| Grade 2 | 1 (0.6%) | 10 (6.0%) |
| Grade unknown | 1 (0.6%) | – |
Skin adverse events were defined as radiodermatitis, ulceration-necrosis, telangiectasia, atrophy, hyperpigmentation or hypopigmentation. With regard to surgical bed fibrosis, only fibrosis absent on inclusion or of a higher grade on inclusion was considered.